PHASE I/II STUDY OF SNX-111 ADMINISTERED TO TERMINAL PATIENTS IN CHRONIC PAIN

本研究的目的是评价该药的安全性、耐受性和 鞘内注射大剂量SNX-111的镇痛作用 给患有慢性疼痛的绝症患者 对阿片类药物治疗的反应不满意。SNX-111是一种新型的 钙通道阻滞剂，专门阻断N型神经元特异性， 突触前神经中的电压敏感钙通道 终点站。这是一项多中心研究，预计将有30名患者 入学，其中5人将在埃默里大学学习。已经有两名患者被 已评估。目前正在修改该协议，以便重新提交到 广交会。

The objective of this study is to asses the safety, tolerability and analgesic effects of rising doses of SNX-111, administered intrathecally to terminally ill patients who suffer from chronic pain and have had an unsatisfactory response to opioid therapy. SNX-111 is a new type of calcium channel blocker that specifically blocks N-type neuron-specific, voltage-sensitive calcium channels which are found at presynaptic nerve terminals. This is a multicenter study, where 30 patients are expected to enroll, 5 of which will be studied at Emory. Two patients have been evaluated. The protocol is currently being modified for resubmission to the GAC.